Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease

Author(s): Erin Reid, Ajay Nooka, Jawaunna Blackmon, Mary Jo Lechowicz

Journal Name: Current Drug Delivery

Volume 9 , Issue 1 , 2012

Become EABM
Become Reviewer
Call for Editor


The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.

Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [41 - 51]
Pages: 11
DOI: 10.2174/156720112798376005
Price: $65

Article Metrics

PDF: 43